Compare JPMorgan Ultra Short Income ETF (JPST) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Tango Therapeutics Inc. — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.28 (market cap $42.48B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 11.3× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and Tango Therapeutics Inc. for 0 Days on average.
| JPST | TNGX | |
|---|---|---|
Market Cap | $42.48B | $3.75B |
Volume | 7,443,811 | 9,619,106 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $32.90 |
52-Week Low | $50.22 | $7.50 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.31 with minimal daily movement, reflecting its ultra-short bond strategy focused on capital preservation. The technical picture shows bearish momentum with RSI indicators mixed, while fundamental data remains limited for this income-focused ETF. Recent news highlights institutional positioning changes and ongoing investor interest in ultrashort bond strategies amid rate uncertainty.
JPST offers investors exposure to high-quality, short-duration bonds with regular dividend distributions. The fund faces competition from similar ultrashort ETFs and sensitivity to Federal Reserve policy changes. Current market conditions favor cash-alternative strategies, though expense ratios and active management performance remain key considerations for investors seeking yield with minimal risk.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
